Yazar "Erer, Burak" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Assessment of Serum Sialic Acid and Oxidative Stress Parameters in Rheumatoid Arthritis Patients Receiving Anti-TNF-alpha and Conventional Therapies
    (Galenos Yayincilik, 2010) Erer, Burak; Yazıcı, Selma; Yılmaz, Gülsen; Yılmaz, Fatma Meriç; Erer, Betül; Yüksel, Hatice
    Objective: In this study, we aimed to evaluate sialic acid (SA) levels and oxidative stress parameters by measuring nitric oxide metabolites (NOx), thiobarbituric acid-reactive substances (TBARS) and thiol (SH) in rheumatoid arthritis (RA) patients treated with either conventional or anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy. Materials and Methods: Eighty-six RA patients and 20 healthy controls were enrolled in the study. All RA patients fulfilled the American College of Rheumatology (ACR) criteria for RA. Thirty patients were on anti-TNF-a therapy. The rest of the patients were either treated with two or three disease-modifying anti-rheumatic drugs. Health Assessment Questionnaire (HAQ) score and the Disease Activity Score 28 (DAS28) were calculated in all patients. NOx, TBARS, SA, and SH levels were measured in both patients and controls. Results: The SA levels were statistically higher in RA patients than in controls. We found increased levels of TBARS and NOx and decreased levels of SH in both groups, but these results were statistically insignificant. Spearman correlation analysis revealed positive correlation between serum TBARS levels and both NOx (r=0.322, p=0.001) and SA (r=0.242, p=0.017) levels. Conclusion: Our results confirm the role of SA in the pathogenesis of RA and its correlation with oxidative stress. Further studies on larger numbers of subjects and with longer treatment durations are needed to analyze the long-term effects of RA therapies on serum oxidative stress parameters. Turk J Phys Med Rehab 2010;56:182-5.
  • Küçük Resim
    Öğe
    The platelet functions in patients with ankylosing spondylitis: Anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass
    (Taylor & Francis Inc, 2010) Yazıcı, Selma; Yazıcı, Mehmet; Erer, Burak; Erer, Betül; Çalık, Yalkın; Bulur, Serkan; Ataoğlu, Safinaz
    The present study was designed to investigate the interaction between platelet indices (mean platelet volume (MPV), platelet count (PLC) and platelet mass (PLM)), inflammatory markers and disease activity in ankylosing spondylitis (AS) subjects. The effects of anti-TNF-alpha therapy and conventional treatment on platelet indices were also compared. We studied 68 patients with AS (group I, 46 men, age: 36.4 +/- 6.9 years) and as control group 34 age and sex-matched healty subjects. All patients received conventional therapy (CT) at the beginning (Group I). The patients were reevaluated after 3 months according to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score. Group II consisted of 35 subjects who responded to the CT and continued to take the same therapy for 3 months additionally. Group III consisted of 33 subjects who had a high disease activity score (BASDAI > 4) after 3 months and were accepted refractory to the CT therapy. In Group III the treatment was switched to infliximab and continued for 3 months at the standard intravenous dose. Significantly higher baseline MPV, PLC and PLM was reported as compared to controls decreased by therapy (9.12 +/- 1.20 vs. 8.35 +/- 0.94 fl, p < 0.001, 340 +/- 69 vs. 251 +/- 56 (x10
  • Küçük Resim
    Öğe
    The platelet indices in patients with rheumatoid arthritis: Mean platelet volume reflects disease activity
    (Taylor & Francis Inc, 2010) Yazıcı, Selma; Yazıcı, Mehmet; Erer, Burak; Erer, Betül; Çalık, Yalkın; Özhan, Hakan; Ataoğlu, Safinaz
    The present study was designed to investigate the interaction between platelet indices, inflammatory markers and disease activity in rheumatoid arthritis (RA) subjects. The effects of anti-TNF-alpha therapy and conventional treatment on platelet indices were also compared. We studied 97 patients with RA (19 men, 78 women: mean age 51 years) and 33 age and sex-matched healthy subjects as a control group. All RA patients were administered conventional therapy. After 3 months of therapy, 35 subjects who had high disease activity score (DAS28 > 5.1) were grouped as non-responders and were administered infliximab as a TNF-alpha blocker at the standard intravenous dose. Responders to the conventional therapy and non-responders were also compared. At baseline white blood cell (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), platelet count and mean platelet volume (MPV) were significantly higher in patients with RA. Mean platelet volume was positively correlated with DAS28 score (r = 0.27; p = 0.007). These markers of inflammation and platelet indices were substantially decreased after therapy. The reductions were similar in responders to conventional therapy and non-responders (TNF alpha group). In conclusion, we found that MPV was correlated with inflammatory markers and disease activity in patients with RA. Both anti-TNF-alpha and conventional therapy decreases markers of inflammation and platelet indices. MPV can reflect both disease activity and response to treatment.